BVF INC/IL
CIK 1056807 · last filed 2026-05-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.28B
Companies
24
Total Filings
37
Lifetime Open-Market Net
$10.09M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XOMAP | 10%+ Owner | 3,545,545 | $25.46 | $90.29M | $0 | 2 | 2026-05-18 |
| OLMA | Director | 2,103,522 | $9.87 | $20.76M | $0 | 1 | 2025-06-13 |
| ELDN | 10%+ Owner | 2,633,679 | $3.57 | $9.40M | $0 | 1 | 2024-10-31 |
| KYMR | Director | 294,632 | $86.20 | $25.40M | $41.50M | 2 | 2024-01-09 |
| Third Harmonic Bio, Inc. (THRD) Delisted | 10%+ Owner | 2,332,638 | $5.38 | $12.55M | $8.79M | 1 | 2022-12-22 |
| CTI BIOPHARMA CORP (CTIC) Delisted | 10%+ Owner | 1,784,461 | $9.09 | $16.22M | $133.00M | 2 | 2022-03-11 |
| CYTK | 2,760,185 | $70.15 | $193.63M | -$77.57M | 1 | 2020-12-11 | |
| Merus N.V. (MRUS) Delisted | 10%+ Owner | 2,200,035 | $90.00 | $198.00M | $17.24M | 1 | 2020-09-17 |
| IDYA | 10%+ Owner | 1,204,981 | $28.98 | $34.92M | $337.0K | 1 | 2020-07-02 |
| CALA | 10%+ Owner | 658,531 | $0.00 | $198 | $3.03M | 1 | 2019-11-18 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 2,958,503 | $38.00 | $112.42M | $27.11M | 1 | 2019-11-07 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | 10%+ Owner | 772,324 | $13.60 | $10.50M | $0 | 1 | 2019-02-01 |
| XOMA | 10%+ Owner | 355,527 | $41.79 | $14.86M | $6.28M | 1 | 2018-12-10 |
| XENE | 10%+ Owner | 297,464 | $52.10 | $15.50M | $1.82M | 1 | 2017-06-30 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 3,627,610 | $0.04 | $162.2K | $6.94M | 1 | 2016-12-30 |
| LGND | 10%+ Owner | 2,008,834 | $255.54 | $513.34M | -$303.29M | 4 | 2013-11-29 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | 10%+ Owner | 4,555,829 | — | — | $2.95M | 1 | 2013-08-02 |
| CAPS | 10%+ Owner | 3,522,300 | $0.29 | $1.04M | $446.7K | 1 | 2011-07-18 |
| Celera CORP (CRA) Delisted | 10%+ Owner | 38,163,934 | — | — | $167.43M | 2 | 2011-05-17 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | 10%+ Owner | 11,792,914 | $15.50 | $182.79M | -$5.05M | 3 | 2009-08-03 |
| RPRX | 10%+ Owner | 10,960,102 | $54.87 | $601.38M | -$7.29M | 1 | 2009-07-15 |
| RGEN | 10%+ Owner | 5,795,100 | $130.59 | $756.78M | -$14.95M | 1 | 2009-07-08 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 10%+ Owner | 8,308,999 | — | — | $251.8K | 2 | 2008-11-25 |
| AVIGEN INC \DE (AVGN) Delisted | 10%+ Owner | 8,055,315 | — | — | $1.12M | 1 | 2008-11-13 |
Recent Filings · Page 4 of 4
37 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2009-07-08 | RGEN | Sell (S) | −2,710,800 | -$14.95M | EDGAR |
| 2009-05-01 | DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | Sell (S) | −110,000 | -$143.0K | EDGAR |
| 2008-11-25 | EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | Buy (P) | +475,500 | $214.0K | EDGAR |
| 2008-11-14 | EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | Buy (P) | +63,000 | $37.8K | EDGAR |
| 2008-11-14 | LGND | Buy (P) | +542,555 | $729.0K | EDGAR |
| 2008-11-13 | AVIGEN INC \DE (AVGN) Delisted | Buy (P) | +1,513,000 | $1.12M | EDGAR |
| 2008-11-12 | LGND | Buy (P) | +2,394,250 | $3.31M | EDGAR |
Showing 31–37 of 37
Prev
Page 4 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.